Dublin, July 01, 2026 (GLOBE NEWSWIRE) -- The "Glp 1 Analogues Market 2025-2029" has been added to ResearchAndMarkets.com's offering.
The global GLP-1 analogues market is projected to expand significantly, with an estimated growth of USD 100.08 billion from 2024 to 2029. This market is expected to accelerate at a CAGR of 25.3% over the forecast period. The comprehensive report offers a detailed analysis of market size, trends, growth drivers, challenges, and vendor scrutiny involving around 25 participants.
The current market analysis underscores the factors fueling its expansion, including the rising prevalence of type 2 diabetes and obesity, increased awareness, and diagnosis of metabolic disorders. Favorable clinical outcomes and broader indications are also strengthening the market position.
Research methodologies incorporate both primary and secondary data, featuring inputs from key industry stakeholders. The report provides substantial market size data, segmented with regional context and vendor landscapes, alongside evaluations of leading companies. Historical and forecasted data support strategic insights.
The global GLP-1 analogues market is segmented as follows:
By Application
- Type 2 diabetes mellitus
- Obesity management
- Cardiovascular diseases
By Route of Administration
- Subcutaneous injection
- Oral administration
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- The Netherlands
- Asia
- Rest of World (RoW)
Significant drivers for market growth in the coming years include the development of multi-agonist therapies, expanding indications beyond diabetes, and a shift towards oral and longer-acting formulations.
The report on the global GLP-1 analogues market covers the following areas:
- Global GLP-1 analogues market sizing
- Global GLP-1 analogues market forecast
- Global GLP-1 analogues market industry analysis
The detailed vendor analysis aims to enhance client market positioning.
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- Ascendis Pharma AS
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Innovent Biologics Inc.
- Johnson and Johnson Services
- LG Chem Ltd.
- Merck and Co. Inc.
- Novo Nordisk AS
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd.
Insights into emerging trends and challenges are included, enabling strategic planning and market advantage exploitation.
The report meticulously synthesizes data from various sources, analyzing profit, pricing, competition, and promotions through qualitative and quantitative research. The findings provide a reliable, in-depth view of the competitive landscape, equipping stakeholders with the tools to forecast market growth accurately.
For more information about this report visit https://www.researchandmarkets.com/r/n4mfck
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
